Efficacy of Substance Removal by Immunoadsorption With a Selective Plasma Separator

Immunoadsorption with a tryptophan‐conjugated column has a limited capacity and reduces fibrinogen. We speculated that immunoadsorption with a selective plasma separator has higher efficiency in removing immunoglobulins than ordinary immunoadsorption without affecting coagulation factors. This study investigated the efficacy of immunoadsorption with a selective plasma separator in vitro. The sieving coefficients, the pool concentration, and the adsorbed amount were investigated serially with up to 5 L of processed plasma. The sieving coefficients of the selective plasma separator were 0.8, 0.5, and 0.1 for albumin, immunoglobulin G (IgG), and factor 13, respectively. The trend of concentrations for the ordinary plasma separator in the pool reached its nadir at 1.5 L and 3.5 L of plasma processed for IgG, IgG1, or IgG2, and IgG3, respectively. However, the volume was doubled for the selective plasma separator. The trends of fibrinogen and factor 13 concentrations differed significantly between two plasma separators. The trends of the absorbed amount were mirror images of the concentration in the pool. Comparison of the peak amount absorbed indicated that the amounts were almost identical between the two separators for IgG, IgG1, and IgG2. On the other hand, the peak amounts were less for albumin, fibrinogen, and IgG3 with the selective plasma separator than with the ordinary separator. Although further investigations about bradykinin are required, immunoadsorption with the selective plasma separator supports the administration of more frequent and intensive treatments to remove IgG1 or IgG2 without affecting coagulation factors.

[1]  T. Okado,et al.  Removal Characteristics of Immunoadsorption With the Immusorba TR‐350 Column Using Conventional and Selective Plasma Separators , 2016, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[2]  T. Okado,et al.  Removal Characteristics of Immunoglobulin G Subclasses by Conventional Plasma Exchange and Selective Plasma Exchange , 2015, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[3]  T. Okado,et al.  Removal Kinetics of Antibodies Against Glutamic Acid Decarboxylase by Various Plasmapheresis Modalities in the Treatment of Neurological Disorders , 2014, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[4]  T. Rai,et al.  Solute Removal Capacity of High Cut‐Off Membrane Plasma Separators , 2013, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[5]  M. Nangaku,et al.  Differences in Reduction of Coagulation Factor XIII (F13) Between Immunoadsorption Plasmapheresis and Double Filtration Plasmapheresis , 2013, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[6]  N. Hanafusa Theoretical Basis of Pathogenic Substance Removal During Plasmapheresis , 2011, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[7]  A. Kaplan,et al.  The plasma bradykinin-forming pathways and its interrelationships with complement. , 2010, Molecular immunology.

[8]  F. Dekker,et al.  Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1 , 2008, Journal of Neuroimmunology.

[9]  N. Shibuya,et al.  Plasmapheresis affects T helper type-1/T helper type-2 balance of circulating peripheral lymphocytes. , 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[10]  G. Matic,et al.  Background and indications for protein A-based extracorporeal immunoadsorption. , 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[11]  F. Rosenow,et al.  Immunoadsorption in Guillain-Barré syndrome and myasthenia gravis. , 2000, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[12]  B. Krämer,et al.  Extracorporal therapy with AN69 membranes in combination with ACE inhibition causing severe anaphylactoid reactions: still a current problem? , 2000, Clinical nephrology.

[13]  D. Hofmann,et al.  Removal of immunoglobulins by a protein A versus an antihuman immunoglobulin G-based system: evaluation of 602 sessions of extracorporeal immunoadsorption. , 2000, Artificial organs.

[14]  G Samuelsson,et al.  What's happening? Protein A columns: current concepts and recent advances. , 1999, Transfusion science.

[15]  H. Okada,et al.  Elevated bradykinin and decreased carboxypeptidase R as a cause of hypotension during tryptophan column immunoabsorption therapy. , 1998, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[16]  M. Yoshida,et al.  Immusorba TR and Immusorba PH: basics of design and features of functions. , 1998, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[17]  K. Hirata,et al.  Ability to remove immunoglobulins and anti-ganglioside antibodies by plasma exchange, double-filtration plasmapheresis and immunoadsorption , 1998, Journal of the Neurological Sciences.

[18]  M. Takamori,et al.  Specific removal of antiacetylcholine receptor antibodies in patients with myasthenia gravis , 1996 .

[19]  N. Yuki Tryptophan-immobilized column adsorbs immunoglobulin G anti-GQ1b antibody from Fisher's syndrome , 1996, Neurology.

[20]  M. Takamori,et al.  Specific removal of anti-acetylcholine receptor antibodies in patients with myasthenia gravis. , 1996, Transfusion science.

[21]  R. Watt,et al.  Therapeutic protein A immunoadsorption. A review , 1990 .